|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,631.90 INR | -0.14% |
|
-2.22% | -5.11% |
| Jan. 23 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday | MT |
| Jan. 23 | Sector Update: Health Care | MT |
Business description: Sun Pharmaceutical Industries Ltd.
- generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment;
- other (6%) : primarily active pharmaceutical ingredients.
At the end of March 2021, the group had 44 production plants worldwide.
Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
Number of employees: 43,000
Sales by Activity: Sun Pharmaceutical Industries Ltd.
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Pharmaceuticals | 335B | 387B | 439B | 485B | 526B |
Geographical breakdown of sales: Sun Pharmaceutical Industries Ltd.
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
India | 109B | 134B | 142B | 154B | 174B |
United States of America | 104B | 117B | 140B | 159B | 170B |
Emerging Markets | 64.05B | 72.76B | 85.63B | 92.42B | 99.56B |
Rest of The World | 54.28B | 59.73B | 65.83B | 72.35B | 77.02B |
Executive Committee: Sun Pharmaceutical Industries Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 2025-08-31 | |
| Director of Finance/CFO | 57 | 2025-06-30 | |
Sinha Dheeraj
CTO | Chief Tech/Sci/R&D Officer | 55 | 2024-04-02 |
Anoop Deshpande
CMP | Compliance Officer | - | 2022-01-30 |
Composition of the Board of Directors: Sun Pharmaceutical Industries Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 73 | 2018-05-24 | |
| Director/Board Member | 70 | 2021-05-20 | |
Rama Bijapurkar
BRD | Director/Board Member | 68 | 2021-05-20 |
Aalok Shanghvi
BRD | Director/Board Member | - | 2023-05-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 65 | 2023-06-14 |
| Director/Board Member | 39 | 2025-05-21 |
Company details: Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
CTS No. 201 B/1, Sun House
400063, Mumbai
+91 22 4324 4324
http://www.sunpharma.com
Group companies: Sun Pharmaceutical Industries Ltd.
| Name | Category and Sector |
|---|---|
Sun Pharmaceutical Industries (Australia) Pty Ltd.
 Sun Pharmaceutical Industries (Australia) Pty Ltd. Wholesales drugs | |
Sun Pharma (Netherlands) BV
 Sun Pharma (Netherlands) BV Operates pharmacy | |
Sun Pharma (Netherlands) BV
Sun Pharma (Netherlands) BV Operates pharmacy | |
Sun Pharma Laboratories Ltd.
 Sun Pharma Laboratories Ltd. Operates as a pharmaceutical company | |
Sun Pharma Laboratories Ltd.
Sun Pharma Laboratories Ltd. Operates as a pharmaceutical company |
Generic Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.14% | -2.22% | -11.00% | +55.52% | 42.62B | |
| +2.36% | +3.63% | +17.51% | +124.30% | 31.27B | |
| -4.04% | -5.90% | -9.38% | +23.76% | 11.56B | |
| -0.37% | +1.60% | -10.83% | +98.51% | 9.66B | |
| -0.89% | +0.90% | +42.95% | +131.33% | 7.99B | |
| -0.41% | -6.36% | +62.32% | +32.66% | 7.87B | |
| -.--% | +0.14% | - | - | 6.79B | |
| +1.04% | +1.19% | +43.10% | -21.20% | 6.81B | |
| -1.48% | -1.65% | +30.23% | +369.95% | 6.04B | |
| -1.14% | -0.48% | -0.86% | +24.57% | 5.85B | |
| Average | -0.51% | -0.83% | +18.23% | +93.27% | 13.65B | |
| Weighted average by Cap. | -0.01% | -0.54% | +9.03% | +84.99% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUNPHARMA Stock
- Company Sun Pharmaceutical Industries Ltd.
Select your edition
All financial news and data tailored to specific country editions
